RE:RE:U.S. lawmakers to investigate approval, pricing of AlzheimerSo we move into a potential opportunity where PMN310 could prove that they have a drug that works better then Aduhelm and has addressed the concerning side effects Aduhelm has...but even more desirable with this recent controversy, a drug that will cost much less then the Aduhelm . I go back to a few years ago when PMN first revealed their completed PMN310.... for some reason I remember hearing this number a few times from various people talking around the camp fire having a beer.... " $4 a dose to manufacture" . Look at it this way .. Biogen and others before have been the ones that have invested 100"s millions of dollars in R&D in the development and clinicals for their AD drugs. PMN has taken the approach of waiting and watching what happens with each expensive process and then tweeking PMN310 to deal with shortcomings identified by the other companies. These other companies have done all our expensive work . Those expenses have to be recovered , so how do you do it... charge some pretty high prices on the end product. I could see PMN coming out with some really amazing prices compared to these other large companies .. dont get me wrong .. the prices could be significantly lower then our competitors but still rediculously profitable , when you look at money spent on R&D and money returning. Again you turn the public opinion with something everybody is fcusing on 1) product that works better with little or no known sdieeffects 2) a price that is considered more then exceptable by these concerned people.